Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol

Abstract

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of, e.g., a MetAP-2 inhibitor.

1 .- 63 . (canceled) 
     
     
         64 . A method for treating obesity in a human patient having an initial body mass index at least about 30 kg/m 2 , or at least about 27 kg/m 2  and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering once weekly to said patient about 1.8 mg of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof. 
     
     
         65 . The method of  claim 64 , wherein parenterally administering is subcutaneously administering. 
     
     
         66 . The method of  claim 64 , wherein parenterally administering is intravenously administering. 
     
     
         67 . The method of  claim 64 , wherein administering to the patient once weekly is repeated until a desired weight is achieved. 
     
     
         68 . A method for treating obesity in a human patient having an initial body mass index at least about 30 kg/m 2 , or at least about 27 kg/m 2  and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering once weekly to said patient about 2.5 mg of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof. 
     
     
         69 . The method of  claim 68 , wherein parenterally administering is subcutaneously administering. 
     
     
         70 . The method of  claim 68 , wherein parenterally administering is intravenously administering. 
     
     
         71 . The method of  claim 68 , wherein administering to the patient once weekly is repeated until a desired weight is achieved. 
     
     
         72 . A method for treating obesity in a human patient having an initial body mass index at least about 30 kg/m 2 , or at least about 27 kg/m 2  and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering once weekly to said patient about 3.0 mg of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof. 
     
     
         73 . The method of  claim 72 , wherein parenterally administering is subcutaneously administering. 
     
     
         74 . The method of  claim 72 , wherein parenterally administering is intravenously administering. 
     
     
         75 . The method of  claim 72 , wherein administering to the patient once weekly is repeated until a desired weight is achieved.